Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 81Leukemia, Myeloid, Acute 75Multiple Myeloma 71Breast Neoplasms 70Lymphoma, Non-Hodgkin 62Lymphoma 62Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 53Recurrence 51Myelodysplastic Syndromes 50Lymphoma, Follicular 49Lymphoma, B-Cell 48Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Melanoma 34Hodgkin Disease 34Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Neoplasm Metastasis 22Pancreatic Neoplasms 21Leukemia, Biphenotypic, Acute 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Malignant Neoplasm × Cyclophosphamide × 1 year × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡